Annual report pursuant to Section 13 and 15(d)

8. Hybrid Debt Instrument (Details Narrative)

v3.7.0.1
8. Hybrid Debt Instrument (Details Narrative) - USD ($)
12 Months Ended
Dec. 31, 2016
Dec. 31, 2015
Loss on conversion $ (6,394,921) $ 0
Interest expense $ 727,000 262,000
SPA Note [Member]    
Convertible note face value   $ 3,000,000
Debt stated interest rate   10.00%
Warrants issued with note   10,000,000
Conversion price   $ 0.15
Hybrid Debt Instrument [Member] | Pharmsynthez [Member]    
Stock issued for convertible note, shares issued 1,373,036  
Stock issued for convertible note, amount converted $ 6,500,000  
Accrued interest converted 228,000  
Loss on conversion $ (6,200,000)  
Additional APA Note [Member] | Pharmsynthez [Member]    
Warrants issued 50,505  
Jr. Secured Convertible Promissory Note [Member] | M. Scott Maguire [Member]    
Convertible note face value $ 369,958  
Warrants issued 37,369  
Interest expense $ 13,176  
Further Notes [Member]    
Warrants issued 50,505  
Further Notes [Member] | Note 1 [Member]    
Convertible note face value $ 178,000  
Further Notes [Member] | Note 2 [Member]    
Convertible note face value $ 322,000